ライフサイエンスコーパス: high-grade

1 neoplasms in this group ranging from low to high grade.

2 17, WHO IV: 13, without biopsy low-grade: 1, high-grade: 1) were investigated with a hybrid PET/MR sc

3 atures were extracted from 40 tumor VOIs (26 high-grade), 36 BPH VOIs, 6 prostatitis VOIs, and 37 hea

4 benign ovarian tumors (3), low grade (4) and high grade (5) serous tumors, and endometrioid tumors (6

5 18 years or older with intermediate-grade or high-grade advanced liposarcoma or leiomyosarcoma who ha

6 s placed hyperglycemia among the most common high grade adverse events.

7 nts with advanced melanoma, albeit with more high-grade adverse events.

8 ssion of low-grade fibrillary astrocytoma to high-grade anaplastic gliomas.

9 hat were found via histologic analysis to be high grade and normal.

10 in a large European cohort, with a focus on high-grade and advanced-stage tumors, and death due to p

11 cancer in comparison with breast carcinoma, high-grade and basal-like tumors respectively.

12 y higher risk of prostate cancer, especially high-grade and lethal prostate cancer.

13 human neoplasms, including germ cell tumors, high-grade and low-grade carcinomas and benign tissues.

14 he optimal rCBV ratio to distinguish between high-grade and low-grade glial tumors.

15 e optimal rCBV ratio to discriminate between high-grade and low-grade tumors to be 2.21.

16 Finally, high-grade and recurrent human skin SCC recapitulated th

17 r in the presence of unstable bradycardia or high-grade arteriovenous block in the absence of myocard

18 r in the presence of unstable bradycardia or high-grade arteriovenous block without significant alter

19 ivin as an attractive therapeutic target for high-grade B cell non-Hodgkin's lymphoma.

20 analysis of adult Burkitt lymphoma (BL) and high-grade B-cell lymphoma with BL gene signature (adult

21 e from diffuse large B-cell lymphoma, termed high-grade B-cell lymphoma with translocations involving

22 High-grade B-cell lymphomas (HGBLs) with MYC and BCL2 an

23 in follicular lymphoma, and MYC/BCL2/BCL6 in high-grade B-cell lymphomas are essential for diagnosis.

24 The adult high-grade B-cell lymphomas sharing molecular features w

25 ignaling components was detected in invasive high-grade bladder cancer cells that expressed Vimentin

26 PpIX) for image-guided surgical resection of high-grade brain tumors (glioblastomas).

27 The WASF3 gene is overexpressed in high-grade breast cancer and promotes invasion and metas

28 increased in tumor tissue from patients with high grade but not low grade serous ovarian cancer.

29 ification into normal, low grade cancer, and high grade cancer.

30 maging (31 mutations per sample +/- 15), and high-grade cancer (33 mutations per sample +/- 18) (P =

31 ive in 93.4% of cases, and dedifferentiated (high-grade cancer) in 41.7% of cases at prevalence scree

32 s are observed in patients with asymptomatic high-grade carotid disease versus patients with acutely

33 enhancement (CE) suggested its absence, and high-grade CE, the presence of neovascularization.

34 gh-risk HPV (6537 women living with HIV) and high grade cervical lesions (HSIL-CIN2+; 9288 women livi

35 The primary outcomes were incidence of high-grade cervical disease (cervical intraepithelial ne

36 Little is known about the long-term yield of high-grade cervical intraepithelial neoplasia (CIN) and

37 predict occurrence of residual or recurrent high-grade cervical intraepithelial neoplasia of grade t

38 or cervical screening increases detection of high-grade cervical intraepithelial neoplastic lesions a

39 cytobrush and rayon swabs from 30 women with high-grade cervical precancer.

40 he per-protocol population, the incidence of high-grade cervical, vulvar and vaginal disease related

41 included low-grade CIN (grade 1 [CIN1]) and high-grade CIN (grade 2 [CIN2] and grade 3 [CIN3]).

42 ctions that were hardly ever associated with high-grade CIN and, almost exclusively, represented fals

43 NKG2D ligand expression in tumor cells from high-grade compared with low-grade follicular lymphoma p

44 High-grade CQ-resistant P. vivax is prevalent in eastern

45 h localized lymphadenopathy; the tumor shows high-grade cytology and lacks both BCL2 expression and t

46 n rate, 1.35 per thousand): 419 diagnoses of high-grade DCIS (detection rate, 0.57 per thousand), 388

47 ts] per 1000 women screened) and highest for high-grade DCIS (range, 0.53[271 of 508 817 patients] to

48 versus 34.9% (22 of 63); the sensitivity for high-grade DCIS components was 91.8% (45 of 49) versus 3

49 nstrate persistently high detection rates of high-grade DCIS in two consecutive subsequent screening

50 Conversely, the detection rate of high-grade DCIS remained at the high level found in the

51 Of note, the detection rate for high-grade DCIS showed a significant increase with age (

52 in patients with a clinical diagnosis of non-high-grade DCIS that would preclude active surveillance.

53 f clinical trials randomizing women with non-high-grade DCIS to active surveillance, defined as imagi

54 ears of age with a clinical diagnosis of non-high-grade DCIS who underwent definitive surgical treatm

55 significant proportion of patients with non-high-grade DCIS will harbor invasive carcinoma.

56 termediate-grade DCIS, </= 2.5 cm; cohort 2: high-grade DCIS, </= 1 cm) with each of five strategies:

57 presenting with a clinical diagnosis of non-high-grade DCIS, 8320 (22.2%) had invasive carcinoma bas

58 r low-grade DCIS, test for intermediate- and high-grade DCIS, RT for intermediate- or high-risk score

59 gy for differentiating between low-grade and high-grade DCIS.

60 gene methylation can predict the presence of high-grade disease at histology in women testing positiv

61 3 from >/= 3 + 4, whereas TBRs discriminated high-grade disease from normal lobes better.

62 In those tested, virtually all high-grade disease occurred in the 43.1% of women who we

63 discriminate HPV16-positive women that have high-grade disease or worse.

64 e insights into the progression from low- to high-grade disease.

65 13% for moderate-grade disease, and 17% for high-grade disease; the corresponding risks of any recur

66 High-grade DLBCL and MCL, as well as MF, are frequently

67 rmal cases, usual ductal hyperplasia and low/high grade ductal carcinoma in situ (DCIS).

68 sh between normal and squamous low-grade and high-grade dyskaryosis, and between normal and mixed squ

69 istry on tissue microarrays, containing EAC, high grade dysplasia (HGD), low grade dysplasia (LGD), B

70 etent) mice of the NU/J strain progressed to high grade dysplasia and to carcinoma in situ.

71 h risk adenomas (villous or tubulovillous or high grade dysplasia or size > 1 cm or > 3 adenomatous p

72 d adenoma, n = 4; tubulovillous adenoma with high grade dysplasia, n = 3; villous adenoma, n = 3), an

73 00 person-years among patients with baseline high-grade dysplasia (95% CI 4.2-12.5).

74 00 person-years among patients with baseline high-grade dysplasia (95% CI 8.8-20.7).

75 history of pancreatic cancer (P = 0.027) and high-grade dysplasia (HGD) (P = 0.003) were independent

76 with Barrett's esophagus for progression to high-grade dysplasia (HGD) and esophageal adenocarcinoma

77 egions containing low-grade dysplasia (LGD), high-grade dysplasia (HGD) or carcinoma (C), with 81% se

78 oidy is associated with later development of high-grade dysplasia (HGD) or colorectal cancer.

79 ntify factors associated with progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma

80 However, little is known about their risk of high-grade dysplasia (HGD) or esophageal adenocarcinoma

81 mor multiplicity and burden, protection from high-grade dysplasia and significantly reduced colitis.

82 group comprised 27 non-dysplastic and eight high-grade dysplasia cases, whereas the high-risk group

83 rbored low-grade dysplasia in 6 cases (16%), high-grade dysplasia in 31 cases (81%), and areas of inv

84 creased microbial diversity in patients with high-grade dysplasia in comparison to control patients,

85 The presence of high-grade dysplasia in serrated lesions was uncommon wh

86 Adenocarcinoma or high-grade dysplasia is present in 14.9% of resected pan

87 petent patients, AGWs of HIV+ MSM may harbor high-grade dysplasia or even invasive squamous cell carc

88 99% CI 96-100) and the probability of having high-grade dysplasia or intramucosal adenocarcinoma was

89 3% (5-27), whereas the probability of having high-grade dysplasia or intramucosal adenocarcinoma was

90 Of these, 376 had no dysplasia and 22 had high-grade dysplasia or intramucosal adenocarcinoma.

91 Malignant disease was defined as high-grade dysplasia or invasive adenocarcinoma on resul

92 Malignancies (high-grade dysplasia or invasive neoplasm) developed aft

93 of moderate risk; the probability of having high-grade dysplasia was 14% (9-21).

94 can be detected at the pre-invasive stage of high-grade dysplasia with the novel Cytosponge device.

95 sk factors for malignancy (adenocarcinoma or high-grade dysplasia) occurring in the setting of an MCN

96 tic BE, 22 samples of LGD, and 34 samples of high-grade dysplasia) were identified, randomly assigned

97 adenomas, tubular adenomas >/=10 mm or with high-grade dysplasia, and conventional adenomas with vil

98 /=1 cm; or with villous histologic findings, high-grade dysplasia, or cancer) during follow-up.

99 non-dysplastic cases and five patients with high-grade dysplasia.

100 5) for LGD, and 0.43 (95% CI, 0.36-0.46) for high-grade dysplasia.

101 intraductal papillary mucinous neoplasm had high-grade dysplasia.

102 patients), 51 were non-dysplastic and 14 had high-grade dysplasia.

103 arker candidates for malignant potential and high-grade dysplasia/cancer were identified by an explor

104 nd prostate stem-cell antigen could identify high-grade dysplasia/cancer with an accuracy of 96% (95%

105 essile serrated adenomas/polyps, 70 sporadic high-grade dysplastic adenomas, and 19 hyperplastic poly

106 ndrome--78 low-grade dysplastic adenomas, 57 high-grade dysplastic adenomas, and 31 colon cancer samp

107 ent of premalignant lesions, such as low- or high-grade dysplastic nodules (LGDNs and HGDNs, respecti

108 elapsed, high-grade serous ovarian cancer or high-grade endometrioid cancer, including primary perito

109 onal modulation in earlier studies that used high-grade equipment in laboratory settings.

110 atic soft-tissue sarcoma, of intermediate or high grade, for which no standard curative therapy was a

111 glia and macrophages (GAM), which infiltrate high-grade gilomas, constitute a major cellular componen

112 amycin (mTOR) is prominently dysregulated in high-grade glial brain tumors, blockade of PI3K or AKT m

113 c Nestin-tumor virus A (Ntva) mouse model of high-grade glioblastoma.

114 t common diagnoses were meningioma (37%) and high-grade glioma (20%).

115 lowed clear differentiation between low- and high-grade glioma (area under the receiver operating cha

116 in low-grade glioma (AUC, 0.818) and MTI in high-grade glioma (AUC, 0.854) and for all WHO grades (A

117 rld Health Organization [WHO] grade II) from high-grade glioma (HGG) (WHO grade III or IV).

118 High-grade glioma (HGG) is a group of primary malignant

119 survival benefit was associated with maximal high-grade glioma (HGG) resection and analysed this lite

120 data from 157 unpublished cases of pediatric high-grade glioma and diffuse intrinsic pontine glioma a

121 s to target surface GRP78 as a biomarker for high-grade glioma and to develop effective cell-specific

122 was performed on 10 patients with recurrent high-grade glioma at 5 different institutions within the

123 -expressed GRP78 as a target for suppressing high-grade glioma cell lines.

124 37 proteins differentially expressed across high-grade glioma TMEs.

125 inhibits the progression of KrasG12V-driven high-grade glioma.

126 a multicenter trial involving patients with high-grade glioma.

127 al receptor involved in the proliferation of high-grade glioma.

128 inded radiology review for 133 patients with high-grade glioma.

129 clinically-annotated and genetically-defined high grade gliomas.

130 mal and malignant tissue during resection of high grade gliomas.

131 High-grade gliomas (HGG) are a devastating group of canc

132 In high-grade gliomas (HGG), distinct hierarchical cell pop

133 High-grade gliomas (HGGs) include the most common and th

134 Medulloblastomas (MBs), but not high-grade gliomas (HGGs), demonstrated spatially homoge

135 oversial: the value of maximal resection for high-grade gliomas (HGGs).

136 therefore classified as WHO grade III or IV high-grade gliomas (HGGs).

137 und in a substantial proportion of pediatric high-grade gliomas (pHGG), often in association with TP5

138 rain tumor specimens of 213 patients (mostly high-grade gliomas [89%]) included in the Vienna Cancer

139 e 1 (NTRK1), is a potent oncogenic driver of high-grade gliomas and confers sensitivity to the experi

140 , we examined expression array data of human high-grade gliomas and performed RT-PCR on glioblastoma

141 gh levels of SLFN5 expression correlate with high-grade gliomas and shorter overall survival in patie

142 Despite multimodality treatment, most high-grade gliomas eventually recur and are ultimately i

143 Current therapies for high-grade gliomas extend survival only modestly.

144 c mutations of H3F3A in aggressive pediatric high-grade gliomas generate K27M or G34R/V mutant histon

145 therapeutic anticoagulation in patients with high-grade gliomas given the increased risk of ICH and p

146 aterials and Methods Seventeen patients with high-grade gliomas who had received 10-44 administration

147 ed with patient prognosis in MES, but not PN high-grade gliomas.

148 ts receptor CSF1R are overexpressed in human high-grade gliomas.

149 Tumor VOIs were marked as high-grade (>/=Gleason grade group 3) or not.

150 y 3-gene expression assay that discriminates high-grade (>/=GS7) from low-grade (GS6) cancer and beni

151 Primary and rare high-grade HCC developed in a genetic mouse model.

152 patients, hyperammonemia was associated with high-grade HE and worse 21-day TFS.

153 irus gene transfer vector, for patients with high-grade (HG) BCG-refractory or relapsed NMIBC.

154 and invariably benign behavior despite often high-grade histological appearance.

155 cal abnormalities, and approximately 85% for high-grade histologically proven cervical abnormalities

156 ch plays a crucial role in cancers that have high-grade histology.

157 tion with features of aggressiveness such as high grade, hormone receptor negativity, presence of a b

158 y gene expression data derived from a set of high-grade human gliomas, shows that high Caspase-8 expr

159 limus was associated with substantially more high-grade hyperglycemia (40% v 9%) and rash (24% v 2%).

160 tcomes associated with numerous cancers, but high-grade, immune-related adverse events can occur, par

161 echanistic differences between low-grade and high-grade inflammation induced by E. coli infection.

162 nt injuries, 73 (67.6%) were intermediate to high-grade injuries, 38 of which were associated with ra

163 only four (1.9%) had high-risk lesions (ie, high-grade intraductal papillary mucinous neoplasms or g

164 short-term severe complications (defined as high-grade intraventricular hemorrhage, surgery for abdo

165 beta signaling intermediate, were present in high-grade invasive bladder cancers and associated with

166 st no boost" trial showed that young age and high-grade invasive carcinoma were the most important ri

167 is after adjustment with both small size and high-grade invasive screen-detected cancers.

168 The association of high-grade invasive tumor with IBTR diminished during fo

169 Therefore, patients with high-grade invasive tumors should be monitored closely,

170 nt in 8 samples (21%; 3 low-grade lesions, 4 high-grade lesion, and 1 cancer-containing lesion).

171 ening, an antecedent event to detection of a high-grade lesion, and changes in sexual behaviors and C

172 n discriminating normal and hyperplasia from high-grade lesions (AUC > 0.94).

173 , all cases of high-risk (hr) HPV-associated high-grade lesions and carcinomas in the anogenital regi

174 ng separated histopathologic analysis-proven high-grade lesions from the normal regions, and this ref

175 a-negative, whereas 25 of 31 (81%) AGWs with high-grade lesions or an anal carcinoma were p16INK4a-po

176 n 19 samples (50%; 1 low-grade lesion and 18 high-grade lesions), and only high-risk HPV-types were p

177 n 11 samples (29%; 2 low-grade lesions and 9 high-grade lesions), low-risk and high-risk types were f

178 events infection, cytological abnormalities, high-grade lesions, and cervical procedures related to H

179 ted for important proportions of low- and/or high-grade lesions, but their contribution dropped in IC

180 sk HPV DNA loads were found in low-grade and high-grade lesions, while high high-risk HPV DNA loads w

181 DNA loads were only found in AGWs harboring high-grade lesions.

182 ry myelodysplasia, whereas transformation to high-grade lymphoma occurred in 3 patients who had recei

183 Ccn6(fl/fl);MMTV-Cre mice developed invasive high grade mammary carcinomas with bona fide EMT, histol

184 surrounding stromal tissue is a hallmark of high grade, metastatic cancers.

185 ph node dissection, which disclosed residual high-grade muscle-invasive urothelial cancer extending t

186 ells that are insensitive to ADT, as well as high-grade/NE prostate tumors, are characterized by elev

187 pressed in small cell lung cancer (SCLC) and high-grade neuroendocrine carcinomas.

188 th MN1 alteration (CNS HGNET-MN1)," and "CNS high-grade neuroepithelial tumor with BCOR alteration (C

189 mor with CIC alteration (CNS EFT-CIC)," "CNS high-grade neuroepithelial tumor with MN1 alteration (CN

190 ars with age-adjusted IPI 2,3) of the German High-Grade Non-Hodgkin Lymphoma Study Group were analyze

191 omy for bacillus Calmette-Guerin-refractory, high-grade noninvasive UC.

192 ive study show no elevated risk for overall, high-grade or advanced-stage prostate cancer, or death d

193 l quality colonoscopy, proximal polyps, or a high-grade or large adenoma (>/=20 mm) at baseline (8865

194 g patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were el

195 mproved event-free survival in patients with high-grade osteosarcoma.

196 patients with recurrent, platinum-sensitive, high-grade ovarian carcinoma were classified into one of

197 detect somatic retrotransposition events in high-grade ovarian serous carcinoma.

198 lin E and PKCiota frequent overexpression in high-grade ovarian tumors poses a novel pathway for ther

199 c loss of p120 catenin progressively develop high-grade pancreatic intraepithelial neoplasia (PanIN)

200 ted in increased ADM, decreased formation of high-grade pancreatic intraepithelial neoplasias, and ac

201 ressing SV40T converted carcinoma-in-situ to high-grade papillary urothelial carcinoma.

202 ive study in patients with intermediate- and high-grade PCa, before radical prostatectomy and extende

203 Conclusion High-grade pediatric brain tumors display higher CBF tha

204 diate-grade [moderately differentiated], and high-grade [poorly differentiated], respectively), chrom

205 ed with significantly increased detection of high-grade precancerous cervical lesions compared to cyt

206 found that PPP2R1A expression is elevated in high-grade primary tumor patients with papillary serous

207 g; these findings were highly suspicious for high-grade prostate cancer (Fig 1).

208 ade (HR, 1.14; 95% CI, 1.01 to 1.29) but not high-grade prostate cancer (HR, 0.83; 95% CI, 0.64 to 1.

209 ncidence (HR, 1.02; 95% CI, 0.96 to 1.08) or high-grade prostate cancer incidence (HR, 0.91; 95% CI,

210 non-transformed and neoplastic low-grade and high-grade prostate epithelial tissue from radical prost

211 acterized cases of human prostate cancer and high-grade prostate intraepithelial neoplasia (HGPIN).

212 of Pten loss, with early neoplastic lesions (high-grade prostatic intraepithelial neoplasia) with str

213 in in histologically normal prostate glands, high-grade prostatic intraepithelial neoplasia, invasive

214 elate to optimal field and transformation to high-grade radiation-associated sarcomas.

215 c and pharmacologic suppression of MARCKS in high-grade RCC cell lines in vitro led to a decrease in

216 platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcin

217 to study Entamoeba developmental biology, as high-grade regulated encystation and excystation are rea

218 Of high-grade sarcomas, OSs are among the most curable, wit

219 Transplantable murine models of ovarian high grade serous carcinoma (HGSC) remain an important r

220 ion was observed between androstenedione and high grade serous tumors [ORlog2 = 0.76 (0.60-0.96)].

221 High-grade serous (HGS) ovarian cancer accounts for 90%

222 r cell, and low-grade serous carcinomas from high-grade serous and mucinous carcinomas.

223 Accumulating evidence indicates that ovarian high-grade serous carcinoma (HGSC) originates from fallo

224 Ovarian high-grade serous carcinoma (HGSC) results in the highes

225 for transplantable murine models of ovarian high-grade serous carcinoma (HGSC) with regard to mutati

226 h a significantly increased risk for ovarian high-grade serous carcinoma (HGSC; 3.8% cases vs. 0.2% c

227 r the most common subtype of ovarian cancer, high-grade serous carcinoma, has sparked a major effort

228 be the distal fallopian tube among all cases.High-grade serous carcinomas (HGSCs) are associated with

229 Many high-grade serous carcinomas (HGSCs) of the pelvis are t

230 ancer Genome Atlas (TCGA), of which 169 were high-grade serous carcinomas (HGSCs).

231 I tumors are composed, for the most part, of high-grade serous carcinomas that can be further subdivi

232 s demonstrate a 30-40-fold increased risk of high-grade serous extra-uterine Mullerian cancers (HGSEM

233 18 years or older, had a platinum-sensitive, high-grade serous or endometrioid ovarian, primary perit

234 ne BRCA1 or BRCA2 mutations in patients with high-grade serous ovarian cancer (HGSC) are associated w

235 High-grade serous ovarian cancer (HGSC) is an aggressive

236 TE) is one of the progenitor populations for high-grade serous ovarian cancer (HGSC).

237 ) has been recognized as a site of origin of high-grade serous ovarian cancer (HGSC).

238 erum and tumor tissue from 158 patients with high-grade serous ovarian cancer (HGSOC) and 100 control

239 s and computed tomography (CT) phenotypes of high-grade serous ovarian cancer (HGSOC) and to evaluate

240 UBB is repressed in approximately 30% of high-grade serous ovarian cancer (HGSOC) patients and is

241 computed tomography (CT) imaging features of high-grade serous ovarian cancer (HGSOC), to assess thei

242 e are no approved biomarkers for olaparib in high-grade serous ovarian cancer (HGSOC).

243 LR-high) groups, especially in patients with high-grade serous ovarian cancer (HGSOC).

244 In high-grade serous ovarian cancer (OV), the bulk of genet

245 High-grade serous ovarian cancer is the most common ovar

246 0-1 and histologically confirmed, relapsed, high-grade serous ovarian cancer or high-grade endometri

247 In matched samples from 11 high-grade serous ovarian cancer patients, we detected 2

248 en evaluated multi-omics profiles of primary high-grade serous ovarian cancer tumours (N=357) to deli

249 n performed meta-analysis on the results for high-grade serous ovarian cancer with the results from a

250 ase 2 (beta) (CaMKK2) is highly expressed in high-grade serous ovarian cancer, and we investigated it

251 resent an exceptional case of a patient with high-grade serous ovarian cancer, treated with multiple

252 and are evaluated as a diagnostic probe for high-grade serous ovarian cancer, typically diagnosed at

253 d with the development of drug resistance in high-grade serous ovarian cancer, were examined from pat

254 eatment planning and treatment monitoring of high-grade serous ovarian cancer.

255 r patients with platinum-sensitive, relapsed high-grade serous ovarian cancer.

256 We performed phylogenetic analysis of high-grade serous ovarian cancers (68 samples from seven

257 drug resistance in ovarian and other cancers.High-grade serous ovarian cancers (HGS-OvCa) frequently

258 The lack of effective chemotherapies for high-grade serous ovarian cancers (HGS-OvCa) has motivat

259 ied and overexpressed in a subset of primary high-grade serous ovarian cancers and cell lines.

260 gene is co-amplified with PIK3CA in 29.3% of high-grade serous ovarian cancers and its overexpression

261 potential over clonal populations comprising high-grade serous ovarian cancers.

262 A key feature of high-grade serous ovarian carcinoma (HGSOC) is frequent

263 High-grade serous ovarian carcinoma (HGSOC) is the most

264 tic TP53 mutations are a defining feature of high-grade serous ovarian carcinoma (HGSOC).

265 gen II expression predicts poor prognosis in high-grade serous ovarian carcinoma.

266 cer cell lines and in organoids derived from high-grade serous ovarian carcinomas (HGSOC), an aggress

267 present in peritoneal fluid from women with high-grade serous ovarian carcinomas (HGSOCs).

268 ly, VprBP protein levels were upregulated in high-grade serous ovarian patient tumors, where the FoxM

269 Many cancers, however, including high-grade serous ovarian, oesophageal, and small-cell l

270 s tumor-infiltrating lymphocytes (TILs) from high-grade serous tumors, defined their suppressive capa

271 ort study included 90 comatose patients with high-grade spontaneous subarachnoid hemorrhage who under

272 -infected women have a higher burden of anal high-grade squamous intraepithelial lesions (HSIL) and a

273 e (ASCUS); 2173 with low-grade and 1282 with high-grade squamous intraepithelial lesions (HSILs) diag

274 sisting for >/=2 years and/or progression to high-grade squamous intraepithelial lesions (ie, cervica

275 ingly, here we show that HIF-2alpha inhibits high-grade STS cell growth in vivo, as loss of HIF-2alph

276 esults Mean CBF was significantly higher for high-grade than for low-grade hemispheric (116 mL/min/10

277 sing efficacy, its primary adverse effect is high-grade thrombocytopenia.

278 In 90% of the high-grade TRAMP tumors, a mismatch in perfusion and met

279 kPL values were relatively higher for high-grade TRAMP tumors.

280 ed increased survival and tumor control in a high-grade transgenic orthotopic glioblastoma model.

281 yeloid cells, and prevention of low-grade to high-grade transition.

282 Progression to high-grade triple-negative breast cancer likely occurs i

283 %, respectively), and patients who had fewer high-grade tumors (13% v 64%, respectively) or right-sid

284 disease progression [DP], 13%) versus 33% of high-grade tumors (grade 3 or 4) (complete response, 0%;

285 Finally, liver cancer organoid-generated high-grade tumors exhibited significantly increased extr

286 and 93%, respectively, at the VOI level) and high-grade tumors from other tissue (AUCs of 85%, 79%, a

287 ue (BPH, prostatitis, or healthy tissue) and high-grade tumors from other tissue (low-grade tumors or

288 lating factor-1 receptor (CSF-1R) to regress high-grade tumors in animal models of this cancer.

289 nsgenic murine models and is associated with high-grade tumors in patients.

290 in perfusion and metabolism between low- and high-grade tumors in the transgenic adenocarcinoma of mo

291 High-grade tumors relapsed more frequently early during

292 High-grade tumors require multidisciplinary treatment co

293 was a significant reduction in perfusion in high-grade tumors that associated with increased hypoxia

294 40 +/- standard deviation, 7,703), all other high-grade tumors were hypermutant (mean, 1,589 +/- stan

295 versus lesional tissue and low-grade versus high-grade tumors with 100% accuracy.

296 ry for malignant progression of low-grade to high-grade tumors.

297 phroureterectomy, revealing locally advanced high-grade UC invading the renal parenchyma (pT3).

298 Biopsy confirmed metastatic high-grade UC.

299 fast preselection of urothelial cells, where high-grade urothelial cancer cells are characterized by

300 The ICG pHLIP imaging agent marked high-grade urothelial carcinomas, both muscle invasive a